Legend Biotech Reports Exceptional Phase 1 Data for LB2501 In Vivo CAR-T in R/R B-NHL
LEGN sits 57% above its 52-week low of $16.24.
Summary
Legend Biotech reported strong preliminary Phase 1 clinical data for its novel in vivo CAR-T therapy, LB2501, showing high response rates and a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Key Events · Product Development and Regulatory · LEGN
-
Exceptional Phase 1 Efficacy
In the dose level 2 cohort, LB2501 achieved a 100% objective response rate (6/6 patients) and an 83.3% complete response rate (5/6 patients) in relapsed/refractory B-cell non-Hodgkin lymphoma. All responses were ongoing at the data cutoff.
-
Novel In Vivo CAR-T Therapy
LB2501 is an investigational in vivo CD19/CD20 dual-targeting CAR-T therapy designed to generate CAR-T cells directly within the patient, eliminating the need for ex vivo manufacturing and lymphodepletion.
-
Favorable Safety Profile
The preliminary data showed no dose-limiting toxicities (DLTs), serious adverse events (SAEs), or immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokine release syndrome (CRS) events were all Grade 2 or lower.
-
Upcoming EHA Presentation
Detailed data for LB2501 will be presented during a late-breaking oral session at the European Hematology Association (EHA) 2026 Congress, taking place from June 11-14, 2026.
Analysis · LEGN · Life Sciences
Legend Biotech announced highly promising preliminary Phase 1 clinical data for LB2501, its investigational in vivo CAR-T therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved a 100% objective response rate and an 83.3% complete response rate in the dose level 2 cohort, alongside a favorable safety profile. This data is significant as LB2501 represents a potential 'off-the-shelf' CAR-T treatment, eliminating the complex manufacturing and lymphodepletion steps required for traditional CAR-T therapies, which could dramatically expand patient access and simplify treatment delivery.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $25.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.